

# Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: The Second Event and Some Final Considerations

Guido Rindi<sup>a</sup> Wouter W. de Herder<sup>b</sup> Dermot O'Toole<sup>c</sup> Bertram Wiedenmann<sup>d</sup>

<sup>a</sup>Department of Pathology and Laboratory Medicine, Università degli Studi, Parma, Italy; <sup>b</sup>Department of Endocrinology, Erasmus MC University, Rotterdam, The Netherlands; <sup>c</sup>Department of Gastroenterology, CHU d'Angers, Angers, France; <sup>d</sup>Department of Hepatology and Gastroenterology, Charité Universitätsmedizin, Berlin, Germany

© Free Author Copy – for personal use only

ANY DISTRIBUTION OF THIS ARTICLE WITHOUT WRITTEN CONSENT FROM S. KARGER AG, BASEL IS A VIOLATION OF THE COPYRIGHT.

Written permission to distribute the PDF will be granted against payment of a permission fee, which is based on the number of accesses required. Please contact [permission@karger.ch](mailto:permission@karger.ch)

## The Second Event

With respect to neuroendocrine tumors (NETs), despite guidelines published by expert national and international (European Neuroendocrine Tumor Society – ENETS) groups [1–4], consensus on patient management is difficult to reach, especially in light of the relatively limited evidence available in the current literature. ENETS, as a leading force in the field, managed to define consensus standards on diagnosis and treatment of tumors of foregut origin among international experts [5]. The same premise leading to the consensus guidelines for the management of patients with NETs of foregut origin (stomach, pancreas and upper jejunum) [5] was applied to produce the present set of papers.

Also, a new TNM classification and grading system were proposed as necessary complements [6]. Based on the work already accomplished, ENETS organized a second conference to discuss consensus standards for the diagnosis and treatment of patients with tumors of midgut (lower jejunum, ileum, cecum and appendix) and hindgut (colon and rectum) origin and the liver with metastatic deposits from gastroenteropancreatic NETs. This second Consensus Conference was held in Frascati, Italy, in November 1–4, 2006.

## The Working Format

Fifty-six experts active in the field of digestive endocrine tumors from 18 countries attended the second Consensus Conference. Attendees were invited on the basis of their acumen (proven publication track and clinical practice) in the field on NETs. The attendees represented all medical branches involved in managing patients with gastroenteropancreatic NETs. They were assigned to four working groups according to their specific clinical expertise: (1) Pathology and Genetics (11 participants); (2) Surgery (8 participants); (3) Imaging and Radiology (6 participants), and (4) Medicine and Clinical Pathology (31 participants). The complete list is provided at the end of this commentary, as well as at the end of each of the five following papers.

The Conference was divided sequentially into five sessions devoted to specific topics on an anatomical basis (Small Intestine; Colon and Rectum; Appendix; Metastatic Liver, and Poorly-Differentiated Endocrine Carcinomas of Hindgut and Midgut Origin). The Organizing Committee (the four front authors) prepared in advance a working booklet, reporting the text of the ENETS guidelines with specific questions for different working groups. The booklet was provided to all the participants at the conference venue.

The work was organized such that, after a short case presentation in a plenary session, each working group

gathered separately to discuss group-specific questions. Each session had a chairperson responsible for the case presentation and for conducting the general assembly toward consensus statements. Each working group had a Group Leader responsible for presenting the specific questions and to prepare the group statements to the general assembly. To expedite discussion, Chairmen and Group Leaders received the part of the booklet relevant to their specific session prior to the conference. Once agreement was reached within each group, consensus statements were discussed and approved or rejected by all participants gathered in the general assembly. This procedure was followed for all five sessions. In addition, the TNM staging and grading proposals were discussed as prepared by the Pathology and Genetics working group along each relevant session, amended and finally approved by the plenary session. The program, the booklet with specific queries and the original files with rough consensus statements are made available on the ENETS site ([www.neuroendocrine.net](http://www.neuroendocrine.net)).

Following this, the Organizing Committee defined and approved a specific protocol establishing the design of each paper, the definition of tasks for authors, the general authorship policy and the assignment of different tasks to participants either responsible or most involved in different sessions. The papers were designed to expand and update the previously published ENETS guidelines [3], incorporating the approved consensus statements. The authors were requested to follow the common format used in the guidelines papers of the first Consensus Conference [5]. This format indeed proved to be flexible enough to accommodate different subjects and different authors' views, however not all papers contain the exact same structure. The paper frame proved consistent enough to highlight the specific consensus statements in a practical and user-friendly way.

### **Achievements and Final Remarks**

The five following papers are part of the tangible results of the second Frascati Consensus Conference, a separate and equally important result being the TNM staging/grading proposal for midgut and hindgut NETs [7]. These papers complete the work initiated at the first Frascati Consensus Conference and conclude a project conceived and started by ENETS in winter 2004.

A great effort was made by the Society and by all participants, equally and generously devoting their time, experience and enthusiasm to building the following con-

sensus guidelines. We thank the Society organizational staff for such a long-term endeavor, and all participants for their substantial effort and good will. We believe that standards are possible even for such a complex tumor disease. The following papers are practical and useful instruments for all professionals dealing with patients with digestive NETs and we hope that our message will ultimately have a positive impact on patients' lives.

### **Acknowledgements**

The second Consensus Conference held in Frascati (Rome, Italy) was supported by a generous grant to ENETS from Novartis Oncology. We wish to also thank Elizabeth Zach for her editing of these guidelines papers, as well as the guidelines on foregut tumors.

### **Complete List of Participants**

*The Complete List of Participants of the 'Consensus Conference on the ENETS Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumors, Part 2: Midgut and Hindgut Tumors' Held in Frascati (Rome, Italy), November 1–4, 2006*

Hakan Ahlman, Institute for Surgical Sciences, Department of Surgery, Sahlgrenska sjukhuset, SE-41345 Gothenburg (Sweden); Rudolf Arnold, Wittelsbacherstr. 6, DE-80469 Munich (Germany); Christoph Auernhammer, Medizinische Klinik II, Grosshadern Klinikum der Ludwig-Maximilians-Universität München, Marchioninstr. 15, DE-81377 Munich (Germany); Martyn Caplin, Royal Free Hospital London, Centre for Gastroenterology, London NW3 2QG (UK); Emanuel Christ, Endokrinologie für Erwachsene, Inselspital, Freiburgstrasse, CH-3010 Bern (Switzerland); Anne Couvelard, Hôpital Beaujon, Service de Gastroentérologie, Boulevard Général Leclerc 100, FR-92110 Clichy (France); Wouter de Herder, Department of Internal Medicine, Section of Endocrinology, Erasmus MC, Dr. Molewaterplein 40, NL-3015 GD Rotterdam (The Netherlands); Gianfranco Delle Fave, Ospedale S. Andrea, Via di Grottarossa 1035, IT-00189 Rome (Italy); Barbro Eriksson, Medical Department, Endocrine Unit, University Hospital, SE-75185 Uppsala (Sweden); Massimo Falconi, University of Verona, Medicine and Surgery, General Surgery Section, MED/18 – General Surgery, Via dell'Artigliere 8, IT-37129 Verona (Italy); Diego Ferone, Departments of Internal Medicine and Endocrinological and Metabolic Sciences, University of Genoa, IT-16132 Genoa (Italy); Peter Goretzki, Städtisches Klinikum Neuss, Lukaskrankenhaus, Chirurgische Klinik I, Preussenstr. 84, DE-41456 Neuss (Germany); David Gross, Department of Endocrinology & Metabolism, Hadassah University Hospital, IL-91120 Jerusalem (Israel); Rudolf Hyrdel, University Hospital Martin, II. Internal Medical Department, Kollarova 2 (Street), SK-036 59 Martin (Slovakia); Robert Jensen, National Institutes of Health, Cell Biology Section, Building 10, Room 9C-193, Bethesda, Md (USA); Gregory Kaltsas, G. Genimatas Hospital, Mesogion Ave., GR-10443 Athens (Greece); Fahrettin Keleştimur, Erciyes University Medical School, Department of

Endocrinology and Metabolism, TR-38039 Kayseri (Turkey); Reza Kianmanesh, UFR Bichat-Beaujon-Louis Mourier, Service de Chirurgie Digestive, Hôpital Louis-Mourier, 178, rue des Renouillers, FR-92700 Colombes (France); Günter Klöppel, Institut für Allgemeine Pathologie und Pathologische Anatomie, Universität Kiel, Michaelisstr. 11, DE-24105 Kiel (Germany); Wolfram Knapp, MHH, Klinik für Nuklearmedizin, Carl-Neuberg-Str. 1, DE-30625 Hannover (Germany); Ulrich-Peter Knigge, Department of Surgery, C2122, Rigshospitalet Blegdamsvej, DK-2100 Copenhagen (Denmark); Paul Komminoth, Institute for Pathology, Kantonsspital, CH-5404 Baden (Switzerland); Meike Körner, Institute of Pathology, University of Bern, Murtenstr. 31, Bern (Switzerland); Beata Kos-Kudła, Slaska Akademia Medyczna, Klinika Endokrynologii, ul. 3 Maja 13/15, PL-41800 Zabrze (Poland); Eric Krenning, Erasmus MC, Dr. Molewaterplein 40, NL-3015 GD, Rotterdam (The Netherlands); Matthew Kulke, Dana-Farber Cancer Institute, 44 Binney Street, Dana 1220, Boston, MA 02115 (USA); Larry Kvols, H. Lee Moffitt Cancer Center/University of South Florida, Magnolia Drive 12902, Tampa, FL 33612 (USA); Dik Kwekkeboom, Department of Nuclear Medicine, Erasmus University Medical Center, Dr. Molewaterplein 40, NL-3015 GD Rotterdam (The Netherlands); José Manuel Lopes, IPATIMUP, Rua Dr. Roberto Frias SLN, PT-4200 Porto (Portugal); Riccardo Manfredi, Istituto di Radiologia, Policlinico GB Rossi, Piazzale LA Scuro, IT-37134 Verona (Italy); Anne Marie McNicol, Division of Cancer Sciences and Molecular Pathology, Pathology Department, Royal Infirmary, Castle Street, Glasgow G4 0SF (UK); Bruno Niederle, Universität Wien, Abteilung Chirurgie, Allgemeines Krankenhaus Wien, Währinger Gürtel 18-20, Ebene 3L, AT-1090 Vienna (Austria); Ola Nilsson, Department of Pathology, Sahlgrenska sjukhuset, SE-41345 Gothenburg (Sweden); George Nikou, 68, Plataion Street, GR-15235 Vrillissia/Athens (Greece); Kjell Öberg, Department of Internal Medicine, Endocrine Unit, University Hospital, SE-75185 Uppsala (Sweden); Juan O'Connor, Instituto Alexander Fleming, Crámer 1180, C1426ANZ, Buenos Aires (Argentina); Dermot O'Toole, Service de Gastroentérologie, Centre Hospitalier Universitaire d'Angers, FR-49000 Angers (France); Ulrich-Frank Pape, Charité Universitätsmedizin, Department of Internal Medicine, Division of Hepatology and Gastroenterology, Campus Virchow Klinikum, Augustenburger Platz 1, DE-13353 Berlin (Germany); Marianne

Pavel, Medizinische Klinik I, Universitätsklinikum Erlangen, Krankenhausstr. 12, DE-91054 Erlangen (Germany); Aurel Perren, Universitätsspital Zürich, Departement Pathologie, Histologielabor PATH F1, Schmelzbergstr. 12, CH-8091 Zürich (Switzerland), present address: Institute for Pathology, Klinikum rechts der Isar, Technische Universität München, Ismaninger Str. 22, DE-81657 Munich (Germany); Ursula Plöckinger, Charité Universitätsmedizin, Campus Virchow-Klinikum, Department of Hepatology and Gastroenterology, Augustenburger Platz 1, DE-13353 Berlin (Germany); John Ramage, Department of Gastroenterology, North Hampshire Hospital, Aldermaston Rd, Basingstoke RG249NA, Hants (UK); Jens Ricke, Otto-von-Guericke-Universität Magdeburg, Klinik für Radiologie und Nuklearmedizin, Leipziger Str. 44, DE-29120 Magdeburg (Germany); Guido Rindi, Dipartimento di Patologia e Medicina di Laboratorio, Sezione di Anatomia Patologica, Università degli Studi, via A. Gramsci, 14, IT-43100 Parma (Italy); Philippe Ruzsiewicz, Service de Gastroentérologie, Hôpital Beaujon, 100, Boulevard Général Leclerc, FR-92110 Clichy (France); Ramon Salazar, Institut Català d'Oncologia, Av. Gran Via s/n, ES-08907 Barcelona (Spain); Aldo Scarpa, Department of Pathology, University of Verona, Strada Le Grazie, 8, IT-37134 Verona (Italy); Jean-Yves Scoazec, Anatomie Pathologique, Hôpital Edouard-Herriot, Bâtiment 10, 3, place d'Arsonval, FR-69437 Lyon, Cedex 03 (France); Maria Isabel Sevilla Garcia, Hospital Virgen de la Victoria, C/Colonia Santa Ines s/n, ES-29010 Malaga (Spain); Thomas Steinmüller, Vivantes Humboldt-Klinikum, Chirurgische Klinik, Am Nordgraben 2, DE-13509 Berlin (Germany); Anders Sundin, Uppsala University Hospital, Department of Radiology, SE-75185 Uppsala (Sweden); Babs Taal, Netherlands Cancer Centre, Plesmanlaan 121, NL-1066 CX Amsterdam (The Netherlands); Marie-Pierre Vullierme, Service de Gastroentérologie, Hôpital Beaujon, 100, Boulevard Général Leclerc, FR-92110 Clichy (France); Bertram Wiedenmann, Charité Universitätsmedizin, Department of Internal Medicine, Division of Hepatology and Gastroenterology, Campus Virchow Klinikum, Augustenburger Platz 1, DE-13353 Berlin (Germany); Stefan Wildi, University Hospital of Zürich, Department of Visceral and Transplantation Surgery, CH-8091 Zürich (Switzerland); James C. Yao, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 (USA).

## References

- Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Valimaki M: Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II. Specific NE tumour types. *Acta Oncol* 2004;43:626-636.
- Plöckinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, Goede A, Caplin M, Oberg K, Reubi JC, Nilsson O, Delle Fave G, Ruzsiewicz P, Ahlman H, Wiedenmann B: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). *Neuroendocrinology* 2004;80:394-424.
- Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, Hawkins R, McNicol AM, Reed N, Sutton R, Thakker R, Aylwin S, Breen D, Britton K, Buchanan K, Corrie P, Gillams A, Lewington V, McCance D, Meeran K, Watkinson A: Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. *Gut* 2005;54(suppl 4):iv1-iv16.
- Wiedenmann B: From ENET to ENETS: a long odyssey in the land of small and rare tumors. *Neuroendocrinology* 2004;80:1-12.
- Rindi G, de Herder WW, O'Toole D, Wiedenmann B: Consensus guidelines for the management of patients with digestive neuroendocrine tumors: why such guidelines and how we went about it. *Neuroendocrinology* 2006;84:155-157.
- Rindi G, Klöppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Eriksson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B: TNM staging of foregut (neuro) endocrine tumors: a consensus proposal including a grading system. *Virchows Arch* 2006;449:395-401.
- Rindi G, Klöppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B: TNM staging of midgut and hindgut (neuro)endocrine tumors: a consensus proposal including a grading system. *Virchows Arch* 2007;451:757-762.